Fresolimumab
Based on 2 publication(s) in Google Scholar
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.51%
- CAS 番号: 948564-73-6
- 分子量:144.4 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
MedChemExpress(MCE)の使用を引用している文献 Fresolimumab
More-
Cell Imaging/Staining
-
IF
生物活性
Human IgG4 kappa
Human
TGFB1
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized TGF beta 1/TGFB1 Protein, Human can bind Fresolimumab. The EC50 for this effect is 67.28 ng/mL. -
Flow Cytometry analysis of PC-3 cells labelling TGFB1 (red) with Fresolimumab (anti-TGFB1) (HY-P99020). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG4 kappa (HY-P99003). Black-Unlabelled control, cells without incubation with primary antibody.
化学情報
-
CAS 番号 948564-73-6
-
性状 Liquid
-
分子量 144.4 kDa
-
Color Colorless to light yellow
-
SMILES
[Fresolimumab]
-
別名
GC1008
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Cells
Investigating the Role of TGF-β Signaling Pathways in Human Corneal Endothelial Cell Primary Culture. [Abstract]2023 Jun 14;12(12):1624. PMID: 37371094
Fresolimumab purchased from MedChemExpress. Usage Cited in: Cells. 2023 Jun 14;12(12):1624. [Abstract]
Fresolimumab (Neutralizing antibody against TGF-βs) (10 μg/mL; 7 days). Illustration of cell morphology by phase-contrast images. The images were acquired using a phase-contrast microscope with X10 objective. Cropped images were used to illustrate cell morphology. Scale bar = 100 µm.
Fresolimumab purchased from MedChemExpress. Usage Cited in: Cells. 2023 Jun 14;12(12):1624. [Abstract]
Fresolimumab (Neutralizing antibody against TGF-βs) (10 μg/mL; 4 weeks). Illustrative images. Cell lateral membranes were stained in green by NCAM and the nuclei were counter-stained in blue using DAPI. A higher magnification (X40) was added in order to show the cell morphology. The images were taken in the center of each well. Images of the same magnification were acquired with the same parameters. The scale bar was 200 µm for X10 images and 50 µm for X40 images.
-
Sci Rep
Collagen-derived biomarkers reveal distinct fibrotic responses among cancer-associated fibroblasts. [Abstract]2026 Jun 12. PMID: 42286082
純度とドキュメンテーション
-
データシート (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Song IW, et al. Targeting TGF-β for treatment of osteogenesis imperfecta. J Clin Invest. 2022 Apr 1;132(7):e152571. [Content Brief]
[2]. Lan Y, et al. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses. J Immunother Cancer. 2022 Jul;10(7):e004122. [Content Brief]
[3]. Oude Munnink TH, et al. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models. J Nucl Med. 2011 Dec;52(12):2001-8. [Content Brief]
[4]. Kadam AH, et al. Targeting caveolae to pump bispecific antibody to TGF-β into diseased lungs enables ultra-low dose therapeutic efficacy. PLoS One. 2022 Nov 22;17(11):e0276462. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)